Subscribe to our Email Alerts

ASX Announcements


 
    Final Director's Interest Notice - Dr. John Lambert  
 
    ACCENT Trial Recruitment Progress  
 
    Appendix 4D and Financial Report Half Year ended 30 Sep 22  
 
    Amplia Appoints Dr Christopher Burns CEO & Managing Director  
 
    Quarterly Activities and Cashflow Reports - Sep 2022 Qtr  
 
    Notification regarding unquoted securities - ATX  
 
    AMP886 Activity in Acute Myeloid Leukemia  
 
    AACR Conference Presentation  
 
    CEO Resignation  
 
    Notification regarding unquoted securities - ATX  
 
    Change of Director's Interest Notice - Dr. Warwick Tong  
 
    Change of Director's Interest Notice - Dr. Robert Peach  
 
    Change of Director's Interest Notice - Dr. Christopher Burns  
 
    Change of Director's Interest Notice - Mrs. Jane Bell  
 
    Change of Director's Interest Notice - Dr. John Lambert  
 
    Notification of cessation of securities - ATX  
 
    Amplia Receives $1.8m R&D Tax Incentive  
 
    Results of Annual General Meeting  
 
    CEO & Managing Director Presentation to AGM  
 
    Annual General Meeting - ESOP and New Constitution  
 
    Employee Security Ownership Plan  
 
    Change of Director's Interest Notice - Dr. Warwick Tong  
 
    First Patient Recruited to ACCENT Trial in Pancreatic Cancer  
 
    Quarterly Activities and Cashflow Reports - June 2022 Qtr  
 
    Presentation at Major Pancreatic Cancer Conference  
 
    Notice of Annual General Meeting/Proxy - YE 31 March 2022  
 
    Change of Director's Interest Notice - Dr. Chistopher Burns  
 
    Change of Director's Interest Notice - Dr. Robert Peach  
 
    Change of Director's Interest Notice - Dr. John Lambert  
 
    Change of Director's Interest Notice - Dr. Warwick Tong  
 
    Notification of cessation of securities - ATX  
 
    Application for quotation of securities - ATX  
 
    Annual General Meeting to be held Thursday 25 August 2022  
 
    Registered Office and Principal Place of Business  
 
    Notification of Expiry of Unlisted Options  
 
    Application for quotation of securities - ATX  
 
    AMP945 Shows Efficacy in Model of Lung Fibrosis  
 
    App 4G - Key to Corporate Governance Disclosures  
 
    Corporate Governance Statement  
 
    Preliminary Final Report and Annual Report YE 31 March 2022  
 
    Amplia Receives Second Ethics Clearance for Phase 2 Trial  
 
    Amplia Presentation to 16th Bioshares Biotech Summit  
 
    AMP945 Pre-IND Meeting Outcome  
 
    Quarterly Activities and Cashflow Reports - March 2022 Qtr  
 
    Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients  
 
    Notification of cessation of securities - ATX  
 
    AMP945 Improves Survival in Human Pancreatic Cancer Model  
 
    ATX Abstract accepted for presentation at Cancer Conference  
 
    Sale of Unmarketable Parcels of Shares  
 
    Change of Director's Interest Notice - Jane Bell  
 
    Amplia Investor Presentation - February 2022  
 
    Quarterly Activities and Cashflow Reports - Dec 2021 Qtr  
 
    Notification regarding unquoted securities - ATX  
 
    Amplia Completes Manufacture of AMP945 for Planned Trials  
 
    Application for quotation of securities - ATX  
 
    Application for quotation of securities - ATX  
 
    App 3Y - Change of Director's Interest - Mrs Jane Bell  
 
    App 3Y - Change of Director's Interest - Dr. Chris Burns  
 
    App 3Y - Change of Director's Interest - Dr. Robert Peach  
 
    App 3Y - Change of Director's Interest - Dr. John Lambert  
 
    App 3Y - Change of Directors Interest Notice - Dr. W. Tong  
 
    Proposed issue of securities - ATX  
 
    Update - Application for quotation of securities - ATX  
 
    Results of Extraordinary General Meeting  
 
    Amplia Provides Updated Investor Presentation  
 
    Update - Application for quotation of securities - ATX  
 
    Update - Proposed issue of securities - ATX  
 
    Entitlement Offer Completed  
 
    Amplia Awarded $2.1M R&D Cash Flow Loan  
 
    App 4D and Financial Report Half Year ended 30 Sep 2021  
 
    Notice of Extraordinary General Meeting - 17 Dec 2021  
 
    Summary Results - Successful Phase 1 Clinical Trial AMP945  
 
    Inhibition of FAK by AMP945 in Phase 1 Clinical Trial  
 
    Becoming a Substantial Holder - Acorn Capital Limited  
 
    Application for quotation of securities - ATX  
 
    Change in substantial holding  
 
    Application for quotation of securities - ATX  
 
    Section 708A Cleansing Notice - Share Placement  
 
    Blueflag Holding - Change of Interest of Substantial Holder  
 
    Application for quotation of securities - ATX  
 
    Proposed issue of securities - ATX  
 
    Proposed issue of securities - ATX  
 
    Capital Raising Investor Presentation  
 
    Entitlement Offer Prospectus  
 
    Placement and Underwritten Entitlement Offer to Raise $12.4m  
 
    Amplia and CRUK agree to Amend Licence Terms - AMP886  
 
    Trading Halt  
 
    Quarterly Activities and Cashflow Reports - Sep 2021 Qtr  
 
    Amplia Appoints New Oncology Clinical Advisor  
 
    Amplia Provides Updated Investor Presentation  
 
    Amplia Receives $1.1m R&D Tax Incentive  
 
    Amplia Appoints New Chief Financial Officer  
 
    New Garvan Publication Supports Amplia Phase 2 Design  
 
    Proactive Investors Lifesciences Webinar Presentation  
 
    Amplia to Present at Proactive Investor Lifesciences Webinar  
 
    Phase 2 Trial in First-Line Pancreatic Cancer Patients  
 
    Updated Investor Presentation  
 
    Change of Director's Interest Notice - Jane Bell  
 
    Results of Annual General Meeting  
 
    AGM - Chief Executive Officer's Presentation  
 
    Annual General Meeting Arrangements  
 
    Quarterly Activities and Cashflow Reports and Presentation  
 
    Shareholder Update and Presentation  
 
    App 4G - Key to Corporate Governance Disclosures  
 
    2021 Corporate Governance Statement  
 
    Annual Report to Shareholders - YE 31 March 2021  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Results from Successful Phase 1 Clinical Trial of AMP945  
 
    Financial Report YE 31 March 2021 - Audited  
 
    Amplia and Garvan Enter Into Collaboration Agreement  
 
    Annual General Meeting to be Held 27 August 2021  
 
    Change of Director's Interest - Dr. Lambert Exercise Options  
 
    Application for quotation of securities - ATX  
 
    Application for quotation of securities - ATX  
 
    AMP945 Improves Survival in Pancreatic Cancer Model  
 
    Application for Quotation of Shares - Options Exercised  
 
    App 4E - Preliminary Final Report YE 31 March 2021  
 
    Change in substantial holding  
 
    Section 708A Cleansing Notice - Share Placement  
 
    Appendix 2A - Application for Quotation of Shares  
 
    Appendix 3G - Notification of Issue of Securties - Options  
 
    Proposed issue of Securities - ATX  
 
    Amplia Announces $3.8m Share Placement  
 
    Trading Halt  
 
    Preclinical Data Support Developmnt AMP945 Pancreatic Cancer  
 
    Quarterly Report and Shareholder Update  
 
    Initial Director's Interest Notice - Jane Bell  
 
    Shareholder Update and Presentation  
 
    ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH  
 
    Amplia Completes Dosing in Phase 1 Clinical Study of AMP945  
 
    Amplia Appoints New Non-Executive Director  
 
    Change of Registered Office and Principal Place of Business  
 
    Appendix 2A - Exercise of Options  
 
    Amplia and Garvan Institute Enter Collaboration Agreement  
 
    Amplia Completes Single Dose Study of AMP945  
 
    Amplia Initiates Multiple Dose Study of AMP945  
 
    Appendix 2A - Exercise of Options  
 
    Investor Update - February 2021  
 
    Quarterly Activities and Cashflow Reports - Dec 2020 Qtr  
 
    Appendix 2A - Exercise of Options  
 
    Shareholder Update - 2020 Review  
 
    Amplia Receives $0.53m R&D Tax Incentive  
 
    Appendix 4D and Financial Report Half Year Ended 30 Sep 2020  
 
    Appendix 2A - Allot Shares upon Exercise of Options  
 
    Notice ASX LR 3.11.2 - Change of Exercise Price of Options  
 
    ATX - Sep 2020 Quarter Activities and Cashflow Reports  
 
    Amplia Presentation to Reach Market Services - Meet the CEO  
 
    Response to ASX Price Query  
 
    First Human Dose in Phase 1 Clinical Trial of AMP945  
 
    Change of Director's Interest Notice - Dr. Warwick Tong  
 
    Change of Director's Interest Notice - Dr. Robert Peach  
 
    Change of Director's Interest Notice - Dr. C. Burns  
 
    Section 708A Cleansing Notice - Allotment of Shares  
 
    Appendix 2A - Application for Quotation of Shares  
 
    Results of Annual General Meeting  
 
    CEO Presentation to AGM  
 
    Amplia Receives Ethics Clearance to Conduct Phase 1 Trial  
 
    Appendix 3G - Notification of Issue of Securities - Options  
 
    Amplia Appoints Dr Mark Devlin as Chief Scientific Officer  
 
    Notice of Annual General Meeting & Proxy - YE 31 March 2020  
 
    Change in Substantial Holding - Blueflag Holdings Pty Ltd  
 
    Change in Substantial Holding - Platinum Investment Management Limited  
 
    Change of Director Interest - Dr Lambert - Entitlement Offer  
 
    Change of Directors Interest - Dr W Tong - Entitlement Offer  
 
    Appendix 2A - Retail Entitlement Offer  
 
    Appendix 4G - Key to Corporate Governance Disclosures  
 
    2020 Corporate Governance Statement  
 
    Annual Report to Shareholders - YE 31 March 2020  
 
    Entitlement Offer Completed  
 
    Quarterly Activities and Cashflow Reports - June 2020  
 
    Nucleus Network Appointed to Conduct Phase 1 Clinical Trial  
 
    AGM to be held Friday 18 September 2020  
 
    Change of Director's Interest Notice - Dr. Warwick Tong  
 
    Becoming a substantial holder  
 
    Becoming a substantial holder  
 
    Change in substantial holding  
 
    Appendix 2A - Institutional Entitlement Offer  
 
    Entitlement Offer - Despatch of Retail Offer Booklet  
 
    Institutional Entitlement Offer Completed  
 
    Appendix 3B - Rights Issue  
 
    Entitlement Offer Cleansing Notice  
 
    Capital Raising - Investor Presentation  
 
    Entitlement Offer to Fund Phase 1 Clinical Trial  
 
    Preclinical Toxicology Studies Support Phase1 Clinical Trial  
 
    Trading Halt  
 
    Full Year Statutory Accounts - YE 31 March 2020  
 
    Investor Presentation  
 
    Preliminary Final Report - YE 31 March 2020  
 
    FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis  
 
    Quarterly Activities Report - March 2020 Qtr  
 
    App 4C - Quarterly Cash Flow Report - March 2020 Qtr  
 
    Shares to be Released from Voluntary Escrow  
 
    FDA Awards Orphan Drug Designation for Pancreatic Cancer  
 
    Professor Paul Timpson Joins Amplia's SAB  
 
    Initial Director's Interest Notice - John Lambert  
 
    Final Director's Interest Notice - Behrenbruch  
 
    Final Director's Interest Notice - Wilkinson  
 
    Final Director's Interest Notice - Cooke  
 
    Dr. John Lambert appointed as Managing Director  
 
    Board Restructuring  
 
    Placement Cleasing Statement  
 
    Appendix 4C Cash Flow - Dec 2019 Qtr  
 
    Ceasing to be a substantial holder - Behrenbruch  
 
    Becoming a substantial holder  
 
    Appendix 3B - Placement  
 
    Amplia Therapeutics Undertakes Placement  
 
    Trading Halt  
 
    Change of Registered Office and Principal Place of Business  
 
    Shareholder Update / 2019 Review  
 
    App 4D - Financial Report Half Year Ended 30 Sep 2019  
 
    App 4C - Sep 2019 Qtr Cash Flows Statement  
 
    Change of Director's Interest - Dr Robert Peach - Placement  
 
    Change of Director's Interest - Dr C Behrenbruch - Placement  
 
    Change of Director's Interest - Dr Warwick Tong, Placement  
 
    Placement Cleansing Notice  
 
    App 3B Placement Shares and Options to Directors and Mgt  
 
    Amplia Therapeutics Provides Manufacturing Update  
 
    Results of Annual General Meeting  
 
    Change of Director's Interest - S Wilkinson - Options Lapsed  
 
    Amplia Therapeutics - Quarterly Update  
 
    Change of Director's Interest - Dr Warwick Tong Rights Issue  
 
    Change of Director's Interest - Dr Chris Burns, Rights Issue  
 
    Change of Director's Interest - Andrew Cooke, Rights Issue  
 
    Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr  
 
    RightsIssue Participation Supports Clinical-Enabling Studies  
 
    Amplia Therapeutics - Bioshares Presentation July 2019  
 
    Appendix 4G - Key to Corporate Governance Disclosures  
 
    2019 Corporate Governance Statement  
 
    Notice of Annual General Meeting/Proxy Form  
 
    Annual Report to Shareholders - YE 31 March 2019  
 
    Amplia Therapeutics Reports Lead Candidate Preclinical Data  
 
    Amplia to present to Bioshares Biotech Summit  
 
    Update - July 2019 Newsletter  
 
    Letter to Shareholders - Rights Issue  
 
    Appendix 3B - Rights Issue  
 
    Rights Issue Prospectus  
 
    Financial Report Year Ended 31 March 2019  
 
    Dr John Lambert appointed as new CEO  
 
    Preliminary Rights Issue Details  
 
    Placement Cleansing Notice  
 
    Appendix 3B - Placement $360k  
 
    Capital Raising for Clinical-Enabling Studies  
 
    Preliminary Final Report - Year Ended 31 March 2019  
 
    Appendix 4C - Quarterly Statement of Cash Flows  
 
    European Patent Completes IP Protection in Major Markets  
 
    Amplia Expands Advisory Board  
 
    Update - February 2019 Newsletter  
 
    App 4D Half Year Accounts 30 Sep 2018  
 
    Change of Director's Interest - Wilkinson - Options Expired  
 
    Change of Director's Interest Notice - Andrew Cooke  
 
    Appendix 4C - quarterly  
 
    Amplia Investor Introduction  
 
    Change of Name to Amplia Therapeutics Limited - ATX  
 
    Change of Director's Interest - Cooke - Options  
 
    Change of Director's Interest - Peach - Options  
 
    Change of Director's Interest - Wilkinson - Options  
 
    Appendix 3B - Options